NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced Dual SET ® Pulse Oximetry for Root ®, a highly versatile patient monitoring and connectivity hub. The first application ...

NEUCHATEL, Switzerland-- (BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...

CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...

NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race ...

These promising results-from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population-add to previously published evidence of its strong ...

More than a decade into their partnership, Masimo and GE HealthCare are still finding new ways to combine their respective patient monitoring technologies. In the latest expansion of their ...